Huaren Pharmaceutical Co., Ltd. (300110)
SZSE
2.79
+0.05 (+1.82%)
Closed
Sep 14, 2026
Day's Range
2.732.82
52 wk Range
2.413.66
Financial Statements - 300110 - Huaren Pharmaceutical Co., Ltd.
Revenue
1.32B▼ 2.3%
Net Income
-459.38M▲ 66.3%Net Margin -34.8%
EBITDA
277.61M▲ 4.4%
Free Cash Flow
341.25M▲ 14.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.32B | 1.35B | 1.63B | 1.61B | 1.56B | 1.31B |
| Cost of Goods | 831.91M | 876.82M | 937.20M | 918.71M | 771.34M | 752.34M |
| Gross Profit | 489.53M | 476.33M | 699.05M | 700.78M | 789.50M | 564.25M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 167.90M | 152.14M | 305.98M | 307.86M | 307.35M | 176.20M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -458.94M | -1.35B | 230.51M | 205.85M | 150.25M | 111.63M |
| Income Tax | 447.76K | 7.07M | 37.08M | 24.55M | 16.20M | 14.74M |
| Net Income | -459.38M | -1.36B | 193.42M | 181.30M | 134.05M | 96.88M |
| EPS Basic | -0.3916 | -1.1576 | 0.159 | 0.153 | 0.11 | 0.08 |
| EPS Diluted | -0.3916 | -1.1576 | 0.159 | 0.153 | 0.11 | 0.08 |
| Basic Shares Outstanding | 1.18B | 1.18B | 1.18B | 1.18B | 1.18B | 1.18B |
| Diluted Shares Outstanding | 1.18B | 1.18B | 1.18B | 1.18B | 1.18B | 1.18B |
| Ebit | -416.97M | -1.30B | 292.02M | 270.02M | 213.39M | 122.59M |
| Ebitda | 277.61M | 266.04M | 436.42M | 462.12M | 435.37M | 291.15M |
| Net Income Continuous Operations | -459.38M | -1.36B | 193.42M | 181.30M | 134.05M | 96.88M |
| Minority Interests | -3.51M | -5.64M | -5.36M | -521.79K | -3.64M | -2.26M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
